The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts. In this article, we are ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

11. Capvaxive (pneumococcal disease vaccine): The 21-valent vaccine, approved June 17, covers 84% of pneumococcal disease serotypes in patients 50 and older. Eight of these serotypes are not ...

Physicians should consider surgery a treatment option for patients on dialysis diagnosed with resectable cancer. In a study of patients diagnosed with cancer after initiating hemodialysis, the 3 ...

Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious diseases including COVID, the flu, whooping cough, and respiratory ...

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...